{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T22:33:18Z","timestamp":1722292398892},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2011,10,6]],"date-time":"2011-10-06T00:00:00Z","timestamp":1317859200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1007\/s10096-011-1433-5","type":"journal-article","created":{"date-parts":[[2011,10,4]],"date-time":"2011-10-04T22:46:23Z","timestamp":1317768383000},"page":"1225-1232","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy of chronic hepatitis C therapy with pegylated interferon and ribavirin in patients on methadone maintenance treatment"],"prefix":"10.1007","volume":"31","author":[{"given":"K.","family":"Neukam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. A.","family":"Mira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Gilabert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Claro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. J.","family":"V\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Cifuentes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Garc\u00eda-Rey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Merchante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Almeida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Mac\u00edas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. A.","family":"Pineda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,10,6]]},"reference":[{"key":"1433_CR1","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1002\/hep.1840360712","volume":"36","author":"MJ Alter","year":"2002","unstructured":"Alter MJ (2002) Prevention of spread of hepatitis C. Hepatology 36:S93\u2013S98","journal-title":"Hepatology"},{"key":"1433_CR2","doi-asserted-by":"crossref","first-page":"705","DOI":"10.7326\/0003-4819-144-10-200605160-00004","volume":"144","author":"GL Armstrong","year":"2006","unstructured":"Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ (2006) The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 144:705\u2013714","journal-title":"Ann Intern Med"},{"key":"1433_CR3","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.drugpo.2007.04.004","volume":"18","author":"C Aceijas","year":"2007","unstructured":"Aceijas C, Rhodes T (2007) Global estimates of prevalence of HCV infection among injecting drug users. Int J Drug Policy 18:352\u2013358","journal-title":"Int J Drug Policy"},{"issue":"Suppl 5","key":"1433_CR4","doi-asserted-by":"crossref","first-page":"S263","DOI":"10.1086\/427440","volume":"40","author":"MS Sulkowski","year":"2005","unstructured":"Sulkowski MS, Thomas DL (2005) Epidemiology and natural history of hepatitis C virus infection in injection drug users: implications for treatment. Clin Infect Dis 40(Suppl 5):S263\u2013S269","journal-title":"Clin Infect Dis"},{"key":"1433_CR5","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1086\/600304","volume":"49","author":"M Hellard","year":"2009","unstructured":"Hellard M, Sacks-Davis R, Gold J (2009) Hepatitis C treatment for injection drug users: a review of the available evidence. Clin Infect Dis 49:561\u2013573","journal-title":"Clin Infect Dis"},{"key":"1433_CR6","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.drugalcdep.2010.03.006","volume":"110","author":"I Zeiler","year":"2010","unstructured":"Zeiler I, Langlands T, Murray JM, Ritter A (2010) Optimal targeting of hepatitis C virus treatment among injecting drug users to those not enrolled in methadone maintenance programs. Drug Alcohol Depend 110:228\u2013233","journal-title":"Drug Alcohol Depend"},{"key":"1433_CR7","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s10900-007-9083-3","volume":"33","author":"SH Mehta","year":"2008","unstructured":"Mehta SH, Genberg BL, Astemborski J, Kavasery R, Kirk GD, Vlahov D et al (2008) Limited uptake of hepatitis C treatment among injection drug users. J Community Health 33:126\u2013133","journal-title":"J Community Health"},{"key":"1433_CR8","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1111\/j.1365-2036.2005.02393.x","volume":"21","author":"C Hatem","year":"2005","unstructured":"Hatem C, Minello A, Bresson-Hadni S, Jooste V, Evrard P, Obert B et al (2005) Is the management of hepatitis C patients appropriate? A population-based study. Aliment Pharmacol Ther 21:1007\u20131015","journal-title":"Aliment Pharmacol Ther"},{"key":"1433_CR9","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/S0140-6736(10)60232-2","volume":"375","author":"BM Mathers","year":"2010","unstructured":"Mathers BM, Degenhardt L, Ali H, Wiessing L, Hickman M, Mattick RP et al (2010) HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet 375:1014\u20131028","journal-title":"Lancet"},{"key":"1433_CR10","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/j.1360-0443.2008.02188.x","volume":"103","author":"DM Novick","year":"2008","unstructured":"Novick DM, Kreek MJ (2008) Critical issues in the treatment of hepatitis C virus infection in methadone maintenance patients. Addiction 103:905\u2013918","journal-title":"Addiction"},{"key":"1433_CR11","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1111\/j.1360-0443.2004.00821.x","volume":"99","author":"M Schaefer","year":"2004","unstructured":"Schaefer M, Heinz A, Backmund M (2004) Treatment of chronic hepatitis C in patients with drug dependence: time to change the rules? Addiction 99:1167\u20131175","journal-title":"Addiction"},{"key":"1433_CR12","first-page":"55","volume":"68","author":"G Robaeys","year":"2005","unstructured":"Robaeys G, Buntinx F (2005) Treatment of hepatitis C viral infections in substance abusers. Acta Gastroenterol Belg 68:55\u201367","journal-title":"Acta Gastroenterol Belg"},{"key":"1433_CR13","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.2105\/AJPH.2004.056150","volume":"95","author":"J Farley","year":"2005","unstructured":"Farley J, Vasdev S, Fischer B, Haydon E, Rehm J, Farley TA (2005) Feasibility and outcome of HCV treatment in a Canadian federal prison population. Am J Public Health 95:1737\u20131739","journal-title":"Am J Public Health"},{"key":"1433_CR14","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1002\/hep.21791","volume":"46","author":"M Schaefer","year":"2007","unstructured":"Schaefer M, Hinzpeter A, Mohmand A, Janssen G, Pich M, Schwaiger M et al (2007) Hepatitis C treatment in \u201cdifficult-to-treat\u201d psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects. Hepatology 46:991\u2013998","journal-title":"Hepatology"},{"key":"1433_CR15","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1159\/000104884","volume":"13","author":"AL Krook","year":"2007","unstructured":"Krook AL, Stokka D, Heger B, Nygaard E (2007) Hepatitis C treatment of opioid dependants receiving maintenance treatment: results of a Norwegian pilot study. Eur Addict Res 13:216\u2013221","journal-title":"Eur Addict Res"},{"key":"1433_CR16","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jsat.2010.02.002","volume":"38","author":"M Waizmann","year":"2010","unstructured":"Waizmann M, Ackermann G (2010) High rates of sustained virological response in hepatitis C virus-infected injection drug users receiving directly observed therapy with peginterferon alpha-2a (40KD) (PEGASYS) and once-daily ribavirin. J Subst Abuse Treat 38:338\u2013345","journal-title":"J Subst Abuse Treat"},{"issue":"Suppl 5","key":"1433_CR17","doi-asserted-by":"crossref","first-page":"S321","DOI":"10.1086\/427447","volume":"40","author":"DL Sylvestre","year":"2005","unstructured":"Sylvestre DL (2005) Treating hepatitis C virus infection in active substance users. Clin Infect Dis 40(Suppl 5):S321\u2013S324","journal-title":"Clin Infect Dis"},{"key":"1433_CR18","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.dld.2008.08.009","volume":"41","author":"B Belfiori","year":"2009","unstructured":"Belfiori B, Ciliegi P, Chiodera A, Bacosi D, Tosti A, Baldelli F et al (2009) Peginterferon plus ribavirin for chronic hepatitis C in opiate addicts on methadone\/buprenorphine maintenance therapy. Dig Liver Dis 41:303\u2013307","journal-title":"Dig Liver Dis"},{"key":"1433_CR19","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/hep.20279","volume":"40","author":"S Mauss","year":"2004","unstructured":"Mauss S, Berger F, Goelz J, Jacob B, Schmutz G (2004) A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology 40:120\u2013124","journal-title":"Hepatology"},{"key":"1433_CR20","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1111\/j.1572-0241.2008.02065.x","volume":"103","author":"HL Bonkovsky","year":"2008","unstructured":"Bonkovsky HL, Tice AD, Yapp RG, Bodenheimer HC Jr, Monto A, Rossi SJ et al (2008) Efficacy and safety of peginterferon alfa-2a\/ribavirin in methadone maintenance patients: randomized comparison of direct observed therapy and self-administration. Am J Gastroenterol 103:2757\u20132765","journal-title":"Am J Gastroenterol"},{"key":"1433_CR21","unstructured":"European Association for the Study of the Liver (EASL). Home page at: http:\/\/www.easl.eu . Accessed March 10th, 2011"},{"key":"1433_CR22","unstructured":"European AIDS Clinical Society (EACS) Guidelines: clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. Available online at: http:\/\/www.europeanaidsclinicalsociety.org\/images\/stories\/EACS-Pdf\/3_chronic_hepatitis_b__c.pdf . Accessed March 10th, 2011"},{"key":"1433_CR23","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1053\/j.gastro.2006.05.016","volume":"131","author":"JM S\u00e1nchez-Tapias","year":"2006","unstructured":"S\u00e1nchez-Tapias JM, Diago M, Escart\u00edn P, Enr\u00edquez J, Romero-G\u00f3mez M, B\u00e1rcena R et al (2006) Peginterferon-alfa2a plus ribavirin for 48 versus 72\u00a0weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 131:451\u2013460","journal-title":"Gastroenterology"},{"key":"1433_CR24","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa040842","volume":"351","author":"FJ Torriani","year":"2004","unstructured":"Torriani FJ, Rodr\u00edguez-Torres M, Rockstroh JK, Lissen E, Gonz\u00e1lez-Garc\u00eda J, Lazzarin A et al (2004) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 351:438\u2013450","journal-title":"N Engl J Med"},{"key":"1433_CR25","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1093\/jac\/dkm373","volume":"60","author":"JA Pineda","year":"2007","unstructured":"Pineda JA, Mira JA, Gil de los Santos I, Valera-Bestard B, Rivero A, Merino D et al (2007) Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus\/HIV-coinfected patients. J Antimicrob Chemother 60:1347\u20131354","journal-title":"J Antimicrob Chemother"},{"key":"1433_CR26","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1086\/656235","volume":"51","author":"JA Pineda","year":"2010","unstructured":"Pineda JA, Caruz A, Rivero A, Neukam K, Salas I, Camacho A et al (2010) Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis 51:788\u2013795","journal-title":"Clin Infect Dis"},{"key":"1433_CR27","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jhep.2006.09.019","volume":"46","author":"N Akuta","year":"2007","unstructured":"Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y et al (2007) Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol 46:403\u2013410","journal-title":"J Hepatol"},{"key":"1433_CR28","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.drugalcdep.2010.08.001","volume":"113","author":"P Vickerman","year":"2011","unstructured":"Vickerman P, Martin N, Hickman M (2011) Can hepatitis C virus treatment be used as a prevention strategy? Additional model projections for Australia and elsewhere. Drug Alcohol Depend 113:83\u201385","journal-title":"Drug Alcohol Depend"},{"key":"1433_CR29","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1111\/j.1365-2036.2009.04123.x","volume":"30","author":"F Schmidt","year":"2009","unstructured":"Schmidt F, Janssen G, Martin G, Lorenz R, Loeschke K, Soyka M et al (2009) Factors influencing long-term changes in mental health after interferon-alpha treatment of chronic hepatitis C. Aliment Pharmacol Ther 30:1049\u20131059","journal-title":"Aliment Pharmacol Ther"}],"container-title":["European Journal of Clinical Microbiology &amp; Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-011-1433-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10096-011-1433-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-011-1433-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T05:34:30Z","timestamp":1559108070000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10096-011-1433-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,6]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["1433"],"URL":"https:\/\/doi.org\/10.1007\/s10096-011-1433-5","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,6]]}}}